Sumavel DosePro (sumatriptan succinate needle-free subcutaneous injection) / Endo, UCB - LARVOL DELTA

Zogenix: Annual Report 2012 (Zogenix) - Anticipated expiry of ten patents in US between 2014 to 2026

Anticipated patent expiry • Migraine

Effect of CGRP and sumatriptan on the BOLD response in visual cortex (J Headache Pain) - P=NA, N=18; No changes in brain activity after CGRP (p=0.12) or after PBO (p=0.41); Sumatriptan did not affect brain activity after CGRP (p=0.71) or after PBO (p=0.98); Systemic CGRP or sumatriptan has no direct effects on the BOLD activity in visual cortex

Clinical data • Migraine • Parkinson's Disease

Zogenix reports first quarter 2012 financial results (Globe Newswire) - Sumavel DosePro(sumatriptan injection) highlights includes total revenues of $18.3M achieved in Q1 2012; Net product revenue increased to $9.9M in Q1 2012 up 32% over Q1 2011; During Q1 2012, company continued to achieve growth in Sumavel DosePro product sales and prescriptions; Company fully expect to capitalize on this market segment

Financial update • Migraine

Top biotech pick for 2012: Zogenix (SeekingAlpha) - Assuming that Sumavel DosePro can gain a conservative 1% share of the 12.2M triptan prescriptions per year, this translates into annual Sumavel revenue of $59M according to Zogenix’s projections; Regulatory approval to market Sumavel DosePro has also been granted in Germany, United Kingdom, Denmark, Sweden, & Norway

Financial update • Regulatory update • Migraine

Zogenix reports first quarter 2011 financial results (Globe Newswire) - Q1 '11 US net product revenue for Sumavel was $7.5M, up 10% over the Q4 '10 & total revenue was $9M, up 270% from $2.4M in Q1 '10; Company presented positive P4 results at AAN Annual meeting demonstrating greater overall satisfaction when treating migraine attacks; Company will present pt satisfaction & efficacy data at the Annual Scientific Meeting of the  AHS & IHC Meeting in June 2011

Q1 ’11 financial results • Migraine

Aradigm announces first quarter 2011 financial results (Businesswire) - Total revenue was $0.2M for the Q1 '11 vs. $4M in Q1 '10; Revenue for Q1 '10 reflects the receipt of the milestone payment from Zogenix upon the first US sale of SumavelDosePro and Q1 '11 reflects the quarterly royalty payment from Zogenix for Sumavel product sales

Q1 ’11 financial results • Migraine

Zogenix reports third quarter 2014 financial results (Zogenix Press Release) - "Net product revenue for the third quarter 2014 was $4.1 million, compared to $6.9 million in the third quarter 2013. The third quarter 2013 net product revenue consisted of sales from the SUMAVEL DosePro business, which the Company sold in May 2014 to Endo International plc (Endo)....Contract manufacturing revenue on sales of SUMAVEL DosePro to Endo under the companies' supply agreement for the third quarter 2014 was $4.2 million."

Sales • Migraine